Exacerbation of Psychogenic Movement Disorder by Interferon{alpha} Treatment of Hepatitis C.
Mundt
Adrian P
AP
Sarkar
Rahul
R
Winter
Christine
C
Schaefer
Martin
M
Ströhle
Andreas
A
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015283:Citalopram / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D018450:Disease Progression; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy; D011602:Psychophysiologic Disorders / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy; D011613:Psychotherapy
D000998:Antiviral Agents; D016898:Interferon-alpha; D015283:Citalopram